FDA Grants Full Approval to Pfizer-BioNTech Covid-19 Vaccine

fizer-BioNTech’s Covid-19 vaccine has become the first jab to be granted full approval by the US Food and Drug Administration (FDA).

The vaccine will now be marketed as Comirnaty (koe-mir’-na-tee), for the prevention of Covid-19 disease in individuals above 16 years of age.

The vaccine also continues to be available under emergency use authorization (EUA), including for individuals 12 to 15 years of age and for the administration of a third dose in certain immunocompromised individuals.

“The FDA’s approval of this vaccine is a milestone as we continue to battle the Covid-19 pandemic. While this and other vaccines have met the FDA’s rigorous, scientific standards for emergency use authorization, as the first FDA-approved Covid-19 vaccine, the public can be very confident that this vaccine meets the high standards for safety, effectiveness, and manufacturing quality the FDA requires of an approved product,” said Acting FDA Commissioner Janet Woodcock, M.D.

“While millions of people have already received Covid-19 vaccines, we recognize that for some, the FDA approval of a vaccine may now instill additional confidence to get vaccinated. Today’s milestone puts us one step closer to altering the course of this pandemic in the US.”

Since December 11, 2020, the Pfizer-BioNTech Covid-19 vaccine has been available under EUA in individuals above 16 years of age, and the authorization was expanded to include those between 12 and 15 years of age on May 10, 2021.

EUAs can be used by the FDA during public health emergencies to provide access to medical products that may be effective in preventing, diagnosing, or treating a disease, provided that the FDA determines that the known and potential benefits of a product, when used to prevent, diagnose, or treat the disease, outweigh the known and potential risks of the product.

Similar Articles



Please enter your comment!
Please enter your name here


Most Popular